Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 717

Drug Profile

CX 717

Alternative Names: Ampakine® CX717; CX717

Latest Information Update: 11 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Phase I Spinal cord injuries
  • Preclinical Drug abuse
  • Discontinued Alzheimer's disease; Respiratory insufficiency; Sleep disorders

Most Recent Events

  • 08 Jan 2018 RespireRx plans to file an IND, and initiate a phase II trial investigating the ability of CX 717 to improve breathing in patients with spinal cord injury, during 2018
  • 08 Jan 2018 RespireRx Pharmaceuticals plans further development of CX 717 in Attention deficit hyperactivity disorder
  • 14 Jun 2017 Phase-I clinical trials in Spinal cord injuries (unspecified route) before June 2017 (RespireRx Pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top